Bruce has a BSc in Physics and in Electronic Engineering as well as an MBA. He has extensive experience in the electronics industry from product development through to being a General Manager of a contract manufacturer. Bruce also has substantial management experience running small businesses in NZ. He has been involved in numerous startups and has been and is currently on the board of several of these.
About us
Freedom to access genomic information will change how we view the world around us and the way we live our lives.
Enabling access to genomic information for anyone, anywhere at anytime is our mission.
Meet the world class team behind our technology.
Bruce Fergusson
Bruce Fergusson
Chairman
Graeme Fuller
Graeme Fuller
DirectorGraeme brings a wealth of expertise in both Physics and Electronic Engineering, with a touch of biological sciences. He previously served as the Chief Technology Officer at Ubiquitome. During his tenure Graeme played a pivotal role in overseeing the development of the Liberty 16 from a Proof-of-Concept device into a cost-effective, mass-manufacturable device.
His governance experience includes serving on the board of remote monitoring provider Jupl.
Eddi Tan, PhD
Eddi Tan, PhD
Chief Executive OfficerEddi brings a robust educational background encompassing Veterinary Medicine (DVM) and Medical Microbiology (PhD). With 18 years of scientific research experience, with a focus on the biopharmaceutical and IVD industries for the past 6 years, she has showcased proficiency across diverse domains. Of particular significance is her involvement in establishing, developing, and launching multiple CE-marked in vitro diagnostic (CE-IVD) kits employing real-time PCR technology, including a kit for COVID-19 screening.
Eddi has spearheaded new test development initiatives and led application groups focused on PCR-based genetic tests, resulting in the development of 6 in vitro diagnostic (IVD) kits with CE registration within a year. She has taken on the position of Team Lead and fulfilled pivotal roles, which included delivering internal training and technical support across various departments, encompassing Sales and Marketing, Regulation Affairs, Production, and Lab Services. Her efforts ensured compliance with ISO requirements and streamlined the CE application process.
Since joining Ubiquitome in 2021, Eddi has demonstrated significant growth within the company, engaging in diverse responsibilities such as fostering customer relations and managing technical aspects of collaborations, leading to the issuance of two FDA-EUAs. Her scientific contributions have consistently met high standards, evidenced by the acceptance of her posters at prestigious conferences such as AACC and AMP. Given her proven track record and expanding role within the organization, Eddi is poised to embrace her latest opportunity as CEO with enthusiasm and dedication.
Taylor Verdun
Taylor Verdun
General ManagerTaylor holds Bachelor of Science degrees in Chemical Engineering and Biological Engineering from Montana State University. Prior to Ubiquitome, Taylor was with medical device company whose focus was to optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. Her focus was in post production processes including data entry and quality control functions.
Since joining Ubiquitome in 2020 as Project Support Associate, Taylor has lead Ubiquitome's transition to a medical device company and the implementation of our now ISO13485 certified quality management system. As Product Manager, she broadened her skill set across sales, marketing, operations and R&D, as well as some responsibilities in finance and accounting. As General Manager, her role has continued to grow as she manages day to day operations of Ubiquitome.
David Hirst, PhD
David Hirst, PhD
R&D LeadDavid's initial training was in experimental laser physics. After a several of years of teaching, he worked in Australia and the UK in fiberoptic component manufacture, mostly in test and measurement and high-volume production setups, then moving to specialist test and measurement equipment design. On returning to New Zealand, he continued designing and building test equipment for high-speed telecoms and industrial sensing applications. David then had a brief turn as a trainee patent attorney before returning to test equipment design and production. He brings this multi-disciplinary experience of optics, electronics, mechanics and firmware to his current role.
Mike Reed, PhD
Mike Reed, PhD
AdvisorMike is an executive R&D leader with a diverse career of over 20-years directing product-focused life science and diagnostic research and development organizations. Mike has led the development and commercialization of over 300 products in genomic, cellular, hematology and rapid testing markets, providing him with a deep understanding of the practical requirements of commercializing products in highly regulated environments. He has leveraged this background since 2020 in support of the NIH RADx program and co-founding various start-ups, most recently joining NaviDx Consulting in 2022. He has a PhD from the University of Adelaide and completed the Executive Program in Management at the UCLA Anderson School of Management.
Bryan Poltilove
Bryan Poltilove
AdvisorMr. Poltilove serves as an advisor, consultant, and independent Board Director, helping companies with fund-raising, commercialization, and inorganic growth strategies. Previously, as Operating Partner with BroadOak Capital Partners, Mr. Poltilove led the firm’s investment strategy in Cell and Gene Therapy, Bioproduction, and Cell Biology. Mr. Poltilove joined BroadOak after 12 years with Thermo Fisher Scientific where he served as Vice President and General Manager. Mr. Poltilove started up and led long-range strategy and day-to-day operations for the company’s cell and gene therapy business. He built a team that delivered 50%+ annual growth and championed the acquisition of Brammer Bio. Prior to Thermo Fisher, Mr. Poltilove served as Director of Revenue Strategy & Operations at the Corporate Executive Board and also held several commercial strategy roles with Johnson & Johnson. He holds Bachelor’s degrees in Chemical Engineering and Economics from the Massachusetts Institute of Technology as well as an MBA from the J.L. Kellogg School of Management at Northwestern University.
Byung-In Lee, PhD
Byung-In Lee, PhD
AdvisorByung-In is an expert in clinically oriented genetic analysis and is Vice President of Product Operations at Maverix Biomics. Dr. Lee joined Maverix Biomics in June 2015 having had extensive product development and molecular diagnostic experience in the Next Generation Sequencing (NGS) field, serving most recently as Sr. Director at Pathway Genomics and AltheaDx, where he led biomarker discovery and molecular diagnostic implementation for companion diagnostic development to support clinical trials.
Dr. Lee held managerial roles at Life Technologies Inc. for Research & Development. He earned his doctorate from University of Illinois and was a Postdoctoral Fellow at Lawrence Livermore National laboratory.